Tech Company Financing Transactions
Embera NeuroTherapeutics Funding Round
Embera NeuroTherapeutics, operating out of Sudbury, received $4.5 million from Louisiana Fund and private investors.
Transaction Overview
Company Name
Announced On
8/15/2011
Transaction Type
Venture Equity
Amount
$4,500,000
Round
Series A
Investors
Proceeds Purpose
Proceeds from this financing, combined with development grant funding from the National Institute for Drug Abuse, will support clinical development of EMB-001 through a Phase 1 safety study, enabling Embera's clinical development programs for both smoking cessation and cocaine dependence.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
365 Boston Post Rd. 210
Sudbury, MA 01776
USA
Sudbury, MA 01776
USA
Phone
Website
Email Address
Not Recorded
Overview
Embera is developing a patent-pending drug combination, EMB-001, that addresses significant unmet needs in smoking cessation and cocaine dependence.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Linke
Vice President
Julie Straub
VP - Operations
Gary Connor
VP - Regulatory Affairs
Ann Robbins
Browse more venture capital transactions:
Prev: 8/15/2011: Practice Fusion venture capital transaction
Next: 8/15/2011: TransMedics venture capital transaction
Share this article
News on VC Transactions
We do our best to document all VC transactions involving tech companies. VC transactions reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs